<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9E90A72A-4A7B-4D2D-854B-4DE60094219A"><gtr:id>9E90A72A-4A7B-4D2D-854B-4DE60094219A</gtr:id><gtr:name>St James's University Hospital (Jimmy's)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/864A9845-BA2F-4BF8-AD6D-91B724CF5991"><gtr:id>864A9845-BA2F-4BF8-AD6D-91B724CF5991</gtr:id><gtr:name>Royal Infirmary of Edinburgh</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ECCC96A2-526B-4202-B3E2-547EEB8FE057"><gtr:id>ECCC96A2-526B-4202-B3E2-547EEB8FE057</gtr:id><gtr:name>Newcastle General Hospital</gtr:name><gtr:address><gtr:line1>Westgate Road</gtr:line1><gtr:line2>Newcastle Upon Tyne</gtr:line2><gtr:line3>Tyne and Wear</gtr:line3><gtr:postCode>NE4 6BE</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1B116AEE-BBD8-4B73-93CF-DCB8A5573C94"><gtr:id>1B116AEE-BBD8-4B73-93CF-DCB8A5573C94</gtr:id><gtr:name>National University of Singapore</gtr:name><gtr:address><gtr:line1>National University of Singapore</gtr:line1><gtr:line2>10 Kent Ridge Crescent</gtr:line2><gtr:line4>Singapore</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Singapore</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D3B5235B-CC4A-4B38-8E39-5179BAFB4DE7"><gtr:id>D3B5235B-CC4A-4B38-8E39-5179BAFB4DE7</gtr:id><gtr:name>Birmingham Heartlands Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8A4D0BD0-05BB-4FEE-9572-0A0C664E7BD5"><gtr:id>8A4D0BD0-05BB-4FEE-9572-0A0C664E7BD5</gtr:id><gtr:name>North Manchester General Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/91427003-DFB6-48F9-848A-32A456E1C00F"><gtr:id>91427003-DFB6-48F9-848A-32A456E1C00F</gtr:id><gtr:name>Royal Free Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5D6066EF-3116-4DB9-A313-EA86A562F928"><gtr:id>5D6066EF-3116-4DB9-A313-EA86A562F928</gtr:id><gtr:name>Imperial College Healthcare NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/257C5108-1625-44DA-8C36-1FBC1CEF564E"><gtr:id>257C5108-1625-44DA-8C36-1FBC1CEF564E</gtr:id><gtr:name>King's College Hospital Charitable Trust</gtr:name><gtr:address><gtr:line1>King's College Hospital</gtr:line1><gtr:line2>Denamark Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SE8 9RS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/53A8F4B4-EBD0-4199-B24B-B5008112311D"><gtr:id>53A8F4B4-EBD0-4199-B24B-B5008112311D</gtr:id><gtr:name>Guy's Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5D2B8776-4478-4DDB-A4DE-748C90B8EBAE"><gtr:id>5D2B8776-4478-4DDB-A4DE-748C90B8EBAE</gtr:id><gtr:name>Makerere University</gtr:name><gtr:address><gtr:line1>PO Box 7062</gtr:line1><gtr:line4>Kampala</gtr:line4><gtr:postCode>+256</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Uganda</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F3F5883D-A54E-4ACD-9913-10CDADFD78D1"><gtr:id>F3F5883D-A54E-4ACD-9913-10CDADFD78D1</gtr:id><gtr:name>Brighton and Sussex University Hospitals NHS Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3DD68C71-6946-40A2-B245-AF543E956C1E"><gtr:id>3DD68C71-6946-40A2-B245-AF543E956C1E</gtr:id><gtr:name>Chelsea and Westminster Hospital NHS Foundation Trust</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B32C383C-54D0-426E-8125-51D32979314D"><gtr:id>B32C383C-54D0-426E-8125-51D32979314D</gtr:id><gtr:name>SimCyp Ltd</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:department>Biomedical Sciences</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9E90A72A-4A7B-4D2D-854B-4DE60094219A"><gtr:id>9E90A72A-4A7B-4D2D-854B-4DE60094219A</gtr:id><gtr:name>St James's University Hospital (Jimmy's)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/864A9845-BA2F-4BF8-AD6D-91B724CF5991"><gtr:id>864A9845-BA2F-4BF8-AD6D-91B724CF5991</gtr:id><gtr:name>Royal Infirmary of Edinburgh</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ECCC96A2-526B-4202-B3E2-547EEB8FE057"><gtr:id>ECCC96A2-526B-4202-B3E2-547EEB8FE057</gtr:id><gtr:name>Newcastle General Hospital</gtr:name><gtr:address><gtr:line1>Westgate Road</gtr:line1><gtr:line2>Newcastle Upon Tyne</gtr:line2><gtr:line3>Tyne and Wear</gtr:line3><gtr:postCode>NE4 6BE</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1B116AEE-BBD8-4B73-93CF-DCB8A5573C94"><gtr:id>1B116AEE-BBD8-4B73-93CF-DCB8A5573C94</gtr:id><gtr:name>National University of Singapore</gtr:name><gtr:address><gtr:line1>National University of Singapore</gtr:line1><gtr:line2>10 Kent Ridge Crescent</gtr:line2><gtr:line4>Singapore</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Singapore</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D3B5235B-CC4A-4B38-8E39-5179BAFB4DE7"><gtr:id>D3B5235B-CC4A-4B38-8E39-5179BAFB4DE7</gtr:id><gtr:name>Birmingham Heartlands Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8A4D0BD0-05BB-4FEE-9572-0A0C664E7BD5"><gtr:id>8A4D0BD0-05BB-4FEE-9572-0A0C664E7BD5</gtr:id><gtr:name>North Manchester General Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/91427003-DFB6-48F9-848A-32A456E1C00F"><gtr:id>91427003-DFB6-48F9-848A-32A456E1C00F</gtr:id><gtr:name>Royal Free Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5D6066EF-3116-4DB9-A313-EA86A562F928"><gtr:id>5D6066EF-3116-4DB9-A313-EA86A562F928</gtr:id><gtr:name>Imperial College Healthcare NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/257C5108-1625-44DA-8C36-1FBC1CEF564E"><gtr:id>257C5108-1625-44DA-8C36-1FBC1CEF564E</gtr:id><gtr:name>King's College Hospital Charitable Trust</gtr:name><gtr:address><gtr:line1>King's College Hospital</gtr:line1><gtr:line2>Denamark Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SE8 9RS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/53A8F4B4-EBD0-4199-B24B-B5008112311D"><gtr:id>53A8F4B4-EBD0-4199-B24B-B5008112311D</gtr:id><gtr:name>Guy's Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5D2B8776-4478-4DDB-A4DE-748C90B8EBAE"><gtr:id>5D2B8776-4478-4DDB-A4DE-748C90B8EBAE</gtr:id><gtr:name>Makerere University</gtr:name><gtr:address><gtr:line1>PO Box 7062</gtr:line1><gtr:line4>Kampala</gtr:line4><gtr:postCode>+256</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Uganda</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F3F5883D-A54E-4ACD-9913-10CDADFD78D1"><gtr:id>F3F5883D-A54E-4ACD-9913-10CDADFD78D1</gtr:id><gtr:name>Brighton and Sussex University Hospitals NHS Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3DD68C71-6946-40A2-B245-AF543E956C1E"><gtr:id>3DD68C71-6946-40A2-B245-AF543E956C1E</gtr:id><gtr:name>Chelsea and Westminster Hospital NHS Foundation Trust</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B32C383C-54D0-426E-8125-51D32979314D"><gtr:id>B32C383C-54D0-426E-8125-51D32979314D</gtr:id><gtr:name>SimCyp Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/EAF39237-6F9C-4169-A3F2-E1E730173D24"><gtr:id>EAF39237-6F9C-4169-A3F2-E1E730173D24</gtr:id><gtr:firstName>Saye</gtr:firstName><gtr:surname>Khoo</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/82CB5BD9-215B-45DE-9EB0-07E1554FB31F"><gtr:id>82CB5BD9-215B-45DE-9EB0-07E1554FB31F</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Owen</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5111B809-5C5E-42B3-A7CB-360BEED2004B"><gtr:id>5111B809-5C5E-42B3-A7CB-360BEED2004B</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Back</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/332D8945-8113-46A2-959B-BA84B915F56E"><gtr:id>332D8945-8113-46A2-959B-BA84B915F56E</gtr:id><gtr:firstName>Geraint</gtr:firstName><gtr:otherNames>Rhys</gtr:otherNames><gtr:surname>Davies</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0901364"><gtr:id>AE2F932D-4C5A-4A10-9656-0C8A3B016B69</gtr:id><gtr:title>Modulation of TB-HIV drug interaction by host genetic influences</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0901364</gtr:grantReference><gtr:abstractText>Tuberculosis (TB) and HIV are leading causes of death from infection worldwide, and co-infection is common with each epidemic fuelling the other. Concurrent treatment of both diseases is necessary, yet complex because of drug interactions. Efavirenz (EFV) is the HIV drug of choice when using rifampicin (RIF)-based TB regimens, and likely to remain so for the foreseeable future. EFV exposure is decreased by RIF, but less so than for other HIV drugs. However, people differ considerably in EFV exposure despite standardised dosing: pharmacogenetic variation in their genes (principally cytochrome P450 CYP2B6) accounts for most of these differences. CYP2B6 variant genes are particularly prevalent in some populations, such as black Africans, South Indians and SE Asians, and these are populations where HIV-TB coinfection is also widespread. 

We want to investigate whether the impact of RIF on EFV exposure is different in people who are CYB2B6 poor metabolisers. Our hypothesis is that in these individuals, accessory pathways of EFV elimination are consequently more important, and a ?second hit? on these accessory pathways either through inhibition by another TB drug (isoniazid), or else the added effect of other common genetic variants which impair these pathways, makes these individuals behave differently when RIF is added to EFV. 

We will evaluate this hypothesis firstly through an interaction study of isoniazid given to healthy volunteers receiving EFV+RIF, in whom CYP2B6 genotype has been characterised. Secondly, we will genotype DNA from up to 347 HIV-positive patients receiving EFV+RIF, together with an equivalent number of HIV-positive patients receiving EFV but not RIF, to examine for secondary exposure-modifying genetic effects. 

This proposal combines research expertise from Liverpool with a strong clinical trials environment in Singapore, and an ideal study population where CYP2B6 poor metabolisers are prevalent. The interaction studied is of huge clinical importance. Knowledge gained will inform treatment guidelines for HIV-TB coinfection, and allow disease management to be optimised through a personalised medicines (genotyping) approach, or approach which stratifies treatment strategies for at-risk populations. If proven, these strong pharmacogenetic influences will also impact on the design and selection of partner drugs for new TB regimens.</gtr:abstractText><gtr:technicalSummary>Tuberculosis (TB) and HIV are leading causes of death from infection worldwide, and co-infection is common with each epidemic fuelling the other. Concurrent treatment of both diseases is necessary, yet complex because of drug interactions. Efavirenz (EFV) is the antiretroviral of choice when using rifampicin (RIF)-based TB regimens, and likely to remain so for the foreseeable future. However, strong pharmacogenetic influences result in excessive variability in EFV exposure to the extent that EFV concentrations are not compromised, and may paradoxically increase in a subgroup of cytochrome P450 CYP2B6 ?poor metabolisers?. 

Our hypothesis is that in CYP2B6 poor metabolisers, secondary ?exposure modifying? influences such as other genetic polymorphisms affecting the accessory pathway of EFV metabolism, or inhibition of that pathway by isoniazid (another component of TB therapy) become consequently more important. We will evaluate this hypothesis firstly through an interaction study of isoniazid given to individuals receiving EFV+RIF, stratified by CYP2B6 genotype. Healthy volunteers (N=150) will be screened for CYB2B6 516G T polymorphism, and homozygous GG (N=24) and TT (N=12) individuals recruited into a proportionally unbalanced, factorial, crossover design study of single dose EFV+RIF with, and without isoniazid. Secondly, we will genotype DNA from up to 347 HIV-positive patients receiving EFV+RIF, together with an equivalent number of HIV-positive patients receiving EFV but not RIF, to examine for secondary exposure-modifying genetic effects. Candidate genes included in this analysis are SNPs and other genetic variants in CYP2B6, CYP 2A6, CYP 3A4/5, PXR, ABCB1 and SLCO1B1. For both studies, we will validate genotype:phenotype associations by measuring EFV and its major metabolites in plasma.

This proposal combines research expertise from Liverpool with a strong clinical trials environment in Singapore, and an ideal study population where CYP2B6 poor metabolisers are prevalent. The interaction studied is of huge clinical importance. Knowledge gained will inform treatment guidelines for HIV-TB coinfection, and allow disease management to be optimised through a personalised medicines (genotyping) approach, or approach which stratifies treatment strategies for at-risk populations. If proven, these strong pharmacogenetic influences will also impact on the design and selection of partner drugs for new TB regimens.</gtr:technicalSummary><gtr:fund><gtr:end>2013-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>153297</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College Healthcare NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK PARTITION Network</gtr:description><gtr:id>7221AE0F-D4F5-4841-9EA7-186AD2C0F425</gtr:id><gtr:impact>Sam Nightingale (PhD Thesis submitted Oct 2014)

Nightingale S, Winston A, Letendre S, Michael BD, McArthur JC, Khoo S, Solomon T. Controversies in HIV-associated neurocognitive disorders. Lancet Neurol. 2014 Nov;13(11):1139-1151. doi: 10.1016/S1474-4422(14)70137-1 

ID physicians, Nurologists, pharmacologists</gtr:impact><gtr:outcomeId>545a13a695e318.86766828-7</gtr:outcomeId><gtr:partnerContribution>We set up this network, and are the Network co-ordinators</gtr:partnerContribution><gtr:piContribution>We established a consortium of HIV units to undertake the UK Partition studies (funded by MRC Fellowship award to Sam Nightingale, primary supervisor KHOO. This work was enabled by our research capacity, established through the MRC award.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>St James's University Hospital (Jimmy's)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK PARTITION Network</gtr:description><gtr:id>D879AA68-A8FE-4992-BCBC-F7657A9FBBAF</gtr:id><gtr:impact>Sam Nightingale (PhD Thesis submitted Oct 2014)

Nightingale S, Winston A, Letendre S, Michael BD, McArthur JC, Khoo S, Solomon T. Controversies in HIV-associated neurocognitive disorders. Lancet Neurol. 2014 Nov;13(11):1139-1151. doi: 10.1016/S1474-4422(14)70137-1 

ID physicians, Nurologists, pharmacologists</gtr:impact><gtr:outcomeId>545a13a695e318.86766828-6</gtr:outcomeId><gtr:partnerContribution>We set up this network, and are the Network co-ordinators</gtr:partnerContribution><gtr:piContribution>We established a consortium of HIV units to undertake the UK Partition studies (funded by MRC Fellowship award to Sam Nightingale, primary supervisor KHOO. This work was enabled by our research capacity, established through the MRC award.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Birmingham Heartlands Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK PARTITION Network</gtr:description><gtr:id>DE52AB4A-CC40-4D96-A22C-D433DA4C06DB</gtr:id><gtr:impact>Sam Nightingale (PhD Thesis submitted Oct 2014)

Nightingale S, Winston A, Letendre S, Michael BD, McArthur JC, Khoo S, Solomon T. Controversies in HIV-associated neurocognitive disorders. Lancet Neurol. 2014 Nov;13(11):1139-1151. doi: 10.1016/S1474-4422(14)70137-1 

ID physicians, Nurologists, pharmacologists</gtr:impact><gtr:outcomeId>545a13a695e318.86766828-8</gtr:outcomeId><gtr:partnerContribution>We set up this network, and are the Network co-ordinators</gtr:partnerContribution><gtr:piContribution>We established a consortium of HIV units to undertake the UK Partition studies (funded by MRC Fellowship award to Sam Nightingale, primary supervisor KHOO. This work was enabled by our research capacity, established through the MRC award.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>SimCyp Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SimCyp Ltd</gtr:description><gtr:id>110ED575-A431-4421-82EF-77423532C1EF</gtr:id><gtr:impact>Multidisciplinary - molecular pharmacology, Pharmacokinetic datasets, and population PK modelling (using a top down approach form Liverpool), with a 'bottom up' approach using in-vitro to in vivo extrapolation, and the SimCyp simulator to generate virtual populations. We are primariliy interested in whether both approaches generate convergent or divergent data.</gtr:impact><gtr:outcomeId>dZ5NHDj6Nks-1</gtr:outcomeId><gtr:partnerContribution>Site license and training in simulator software.</gtr:partnerContribution><gtr:piContribution>Provision of PK expertise, and PK data (in vitro and in vivo).
Provision of modelling team to support research
Molecular pharmacology expertise and data</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>Vietnam, Socialist Republic of</gtr:country><gtr:department>Oxford University Clinical Research Unit Vietnam (OUCRU)</gtr:department><gtr:description>Wellcome Tropical Unit Vietnam</gtr:description><gtr:id>17CB1137-A0D5-4DC0-A8F4-C7C14C74D721</gtr:id><gtr:impact>Data currently being analysed</gtr:impact><gtr:outcomeId>ovTrkGsM8TY-1</gtr:outcomeId><gtr:partnerContribution>Provision of samples form RCT for PK analysis</gtr:partnerContribution><gtr:piContribution>Bioanalytical expertise for HIV drugs + drug metabolites</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Chelsea and Westminster Hospital NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK PARTITION Network</gtr:description><gtr:id>E5C6E61F-88DC-4B22-8C67-F306B5C850F0</gtr:id><gtr:impact>Sam Nightingale (PhD Thesis submitted Oct 2014)

Nightingale S, Winston A, Letendre S, Michael BD, McArthur JC, Khoo S, Solomon T. Controversies in HIV-associated neurocognitive disorders. Lancet Neurol. 2014 Nov;13(11):1139-1151. doi: 10.1016/S1474-4422(14)70137-1 

ID physicians, Nurologists, pharmacologists</gtr:impact><gtr:outcomeId>545a13a695e318.86766828-1</gtr:outcomeId><gtr:partnerContribution>We set up this network, and are the Network co-ordinators</gtr:partnerContribution><gtr:piContribution>We established a consortium of HIV units to undertake the UK Partition studies (funded by MRC Fellowship award to Sam Nightingale, primary supervisor KHOO. This work was enabled by our research capacity, established through the MRC award.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Makerere University</gtr:collaboratingOrganisation><gtr:country>Uganda, Republic of</gtr:country><gtr:description>Makarere University</gtr:description><gtr:id>2886AE6F-5062-4032-978C-0043052B1724</gtr:id><gtr:impact>Several research publications, which are listed separately
EDCTP Research Fellowship for Dr Mohammed Lamorde</gtr:impact><gtr:outcomeId>cvJZw4AQ267-1</gtr:outcomeId><gtr:partnerContribution>clinical recruitment</gtr:partnerContribution><gtr:piContribution>Bioanalytical support for HIV/TB clinical drug interaction studies</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Brighton and Sussex University Hospitals NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK PARTITION Network</gtr:description><gtr:id>B1D2A9C7-05F9-4AAD-9000-5189DE0DF641</gtr:id><gtr:impact>Sam Nightingale (PhD Thesis submitted Oct 2014)

Nightingale S, Winston A, Letendre S, Michael BD, McArthur JC, Khoo S, Solomon T. Controversies in HIV-associated neurocognitive disorders. Lancet Neurol. 2014 Nov;13(11):1139-1151. doi: 10.1016/S1474-4422(14)70137-1 

ID physicians, Nurologists, pharmacologists</gtr:impact><gtr:outcomeId>545a13a695e318.86766828-4</gtr:outcomeId><gtr:partnerContribution>We set up this network, and are the Network co-ordinators</gtr:partnerContribution><gtr:piContribution>We established a consortium of HIV units to undertake the UK Partition studies (funded by MRC Fellowship award to Sam Nightingale, primary supervisor KHOO. This work was enabled by our research capacity, established through the MRC award.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK PARTITION Network</gtr:description><gtr:id>3AF55D97-29C4-4B62-BC91-9289466B6BC0</gtr:id><gtr:impact>Sam Nightingale (PhD Thesis submitted Oct 2014)

Nightingale S, Winston A, Letendre S, Michael BD, McArthur JC, Khoo S, Solomon T. Controversies in HIV-associated neurocognitive disorders. Lancet Neurol. 2014 Nov;13(11):1139-1151. doi: 10.1016/S1474-4422(14)70137-1 

ID physicians, Nurologists, pharmacologists</gtr:impact><gtr:outcomeId>545a13a695e318.86766828-9</gtr:outcomeId><gtr:partnerContribution>We set up this network, and are the Network co-ordinators</gtr:partnerContribution><gtr:piContribution>We established a consortium of HIV units to undertake the UK Partition studies (funded by MRC Fellowship award to Sam Nightingale, primary supervisor KHOO. This work was enabled by our research capacity, established through the MRC award.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Infirmary of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK PARTITION Network</gtr:description><gtr:id>5C177A95-891F-4713-B825-E81551804F75</gtr:id><gtr:impact>Sam Nightingale (PhD Thesis submitted Oct 2014)

Nightingale S, Winston A, Letendre S, Michael BD, McArthur JC, Khoo S, Solomon T. Controversies in HIV-associated neurocognitive disorders. Lancet Neurol. 2014 Nov;13(11):1139-1151. doi: 10.1016/S1474-4422(14)70137-1 

ID physicians, Nurologists, pharmacologists</gtr:impact><gtr:outcomeId>545a13a695e318.86766828-10</gtr:outcomeId><gtr:partnerContribution>We set up this network, and are the Network co-ordinators</gtr:partnerContribution><gtr:piContribution>We established a consortium of HIV units to undertake the UK Partition studies (funded by MRC Fellowship award to Sam Nightingale, primary supervisor KHOO. This work was enabled by our research capacity, established through the MRC award.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>North Manchester General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK PARTITION Network</gtr:description><gtr:id>131895CB-BEA1-49B8-ABB0-05018C3EEE50</gtr:id><gtr:impact>Sam Nightingale (PhD Thesis submitted Oct 2014)

Nightingale S, Winston A, Letendre S, Michael BD, McArthur JC, Khoo S, Solomon T. Controversies in HIV-associated neurocognitive disorders. Lancet Neurol. 2014 Nov;13(11):1139-1151. doi: 10.1016/S1474-4422(14)70137-1 

ID physicians, Nurologists, pharmacologists</gtr:impact><gtr:outcomeId>545a13a695e318.86766828-2</gtr:outcomeId><gtr:partnerContribution>We set up this network, and are the Network co-ordinators</gtr:partnerContribution><gtr:piContribution>We established a consortium of HIV units to undertake the UK Partition studies (funded by MRC Fellowship award to Sam Nightingale, primary supervisor KHOO. This work was enabled by our research capacity, established through the MRC award.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle General Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK PARTITION Network</gtr:description><gtr:id>08EBBB44-392A-4D15-9E97-405D7EC07112</gtr:id><gtr:impact>Sam Nightingale (PhD Thesis submitted Oct 2014)

Nightingale S, Winston A, Letendre S, Michael BD, McArthur JC, Khoo S, Solomon T. Controversies in HIV-associated neurocognitive disorders. Lancet Neurol. 2014 Nov;13(11):1139-1151. doi: 10.1016/S1474-4422(14)70137-1 

ID physicians, Nurologists, pharmacologists</gtr:impact><gtr:outcomeId>545a13a695e318.86766828-11</gtr:outcomeId><gtr:partnerContribution>We set up this network, and are the Network co-ordinators</gtr:partnerContribution><gtr:piContribution>We established a consortium of HIV units to undertake the UK Partition studies (funded by MRC Fellowship award to Sam Nightingale, primary supervisor KHOO. This work was enabled by our research capacity, established through the MRC award.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Guy's Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK PARTITION Network</gtr:description><gtr:id>1F0E1D60-C607-4149-BDC7-694BEAF93723</gtr:id><gtr:impact>Sam Nightingale (PhD Thesis submitted Oct 2014)

Nightingale S, Winston A, Letendre S, Michael BD, McArthur JC, Khoo S, Solomon T. Controversies in HIV-associated neurocognitive disorders. Lancet Neurol. 2014 Nov;13(11):1139-1151. doi: 10.1016/S1474-4422(14)70137-1 

ID physicians, Nurologists, pharmacologists</gtr:impact><gtr:outcomeId>545a13a695e318.86766828-3</gtr:outcomeId><gtr:partnerContribution>We set up this network, and are the Network co-ordinators</gtr:partnerContribution><gtr:piContribution>We established a consortium of HIV units to undertake the UK Partition studies (funded by MRC Fellowship award to Sam Nightingale, primary supervisor KHOO. This work was enabled by our research capacity, established through the MRC award.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National University of Singapore</gtr:collaboratingOrganisation><gtr:country>Singapore, Republic of</gtr:country><gtr:department>Pharmacology Singapore</gtr:department><gtr:description>National University of Singapore</gtr:description><gtr:id>FD59BC90-4B78-4469-A1A1-F53A4C891008</gtr:id><gtr:impact>Study just finished recruiting. Data currently being analysed. 

Multidisciplinary- molecular pharmacology, clinical pharmacology, molecular genetics, mathematical modelling, bioanalytical</gtr:impact><gtr:outcomeId>QqKqUXPNQwM-1</gtr:outcomeId><gtr:partnerContribution>provision of samples for cross laboratory quality control, and sending over a senior technician to harmonise practise and for us to assist in technology transfer.</gtr:partnerContribution><gtr:piContribution>Tech transfer for molecular genotyping and bioanalytical expertise. Validating intracellular drug measurement protocols in Liverpool for field use in Singapore.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Free Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK PARTITION Network</gtr:description><gtr:id>5117E613-D746-4401-B2CA-8C2DE933FA02</gtr:id><gtr:impact>Sam Nightingale (PhD Thesis submitted Oct 2014)

Nightingale S, Winston A, Letendre S, Michael BD, McArthur JC, Khoo S, Solomon T. Controversies in HIV-associated neurocognitive disorders. Lancet Neurol. 2014 Nov;13(11):1139-1151. doi: 10.1016/S1474-4422(14)70137-1 

ID physicians, Nurologists, pharmacologists</gtr:impact><gtr:outcomeId>545a13a695e318.86766828-5</gtr:outcomeId><gtr:partnerContribution>We set up this network, and are the Network co-ordinators</gtr:partnerContribution><gtr:piContribution>We established a consortium of HIV units to undertake the UK Partition studies (funded by MRC Fellowship award to Sam Nightingale, primary supervisor KHOO. This work was enabled by our research capacity, established through the MRC award.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>World AIDS Day Schools Lecture &amp; Roadshow</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>76491BA8-4643-428A-9A1E-9C7629CE2643</gtr:id><gtr:impact>over 100 pupils from 5 schools across Merseyside took part in this activity, which was organised by the University, and run in association with the local HIV patient group and a popular DJ from BBC radio Merseyside (Roger Phillips)

Schools asked for further contact and lectures</gtr:impact><gtr:outcomeId>Cm41qVDut8A</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Schools lecture series</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>ECD5F036-D3E6-4471-B2A4-D9DA40E48C71</gtr:id><gtr:impact>Our team (including post-docs) visited schools across Merseyside and gave talks on pathogen-host interactions. They were accompanied by a local artist who then developed artwork projects from these lectures.

exhibition at World Museum Liverpool in 2011.</gtr:impact><gtr:outcomeId>JBFQCVWmJUZ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Art Exhibition at World Museum, Liverpool</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>D4F57DF3-D39A-4A15-8160-883F105A1863</gtr:id><gtr:impact>Schools Art project with local artist (Gaynor Vane) - multimedia artwork depicting TB, HIV and other pathogens in tissue, and interaction between host and pathogen. This accompanied a year-long engagement with schools across Merseyside.

Exhibition at regional museum</gtr:impact><gtr:outcomeId>XQNY33mbPpi</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Video podcast for Greenwich School of Management</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>8746BD9F-F5C4-40C7-93DF-641A5D400320</gtr:id><gtr:impact>Podcast for students on Business managment courses at Greenwich School of Management on HIV. they will seek to raise awareness in their events management activities as part of their final year module.</gtr:impact><gtr:outcomeId>56dedce4c3c950.54015538</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>HIV drug interactions website</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Bristol-Myers Squibb</gtr:fundingOrg><gtr:id>BB714289-1EE7-4E09-9C85-7EDA0F75515F</gtr:id><gtr:outcomeId>56cc47b967be45.53142183</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>European and Developing Countries Clinical Trials Partnership</gtr:department><gtr:description>Integrated Project Special populations and label expansion studies with the fixed dose combinations artemether-lumefantrine, amodiaquine-artesunate, and dihydroartemisinin-piperaquine in Zambia, Malawi and Mozambique</gtr:description><gtr:end>2014-07-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:fundingRef>IP2007.31060.003</gtr:fundingRef><gtr:id>ECF04382-28B2-4DFF-B4C3-601773AA0666</gtr:id><gtr:outcomeId>fMEiwsNac7X</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Janssen Pharmaceutica</gtr:department><gtr:description>HIV drug interactions website</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Johnson &amp; Johnson</gtr:fundingOrg><gtr:id>0C4DFE33-CF70-4918-8069-E80DA7AA3608</gtr:id><gtr:outcomeId>56cc49a8788a86.42056891</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1439979</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>Innovative Medicines Initiative (EU)</gtr:description><gtr:end>2019-07-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>Predict TB Consortium (PI Davies)</gtr:fundingRef><gtr:id>B4F47567-DB7F-473B-BB36-2CD7A0A56D8A</gtr:id><gtr:outcomeId>FCRdCJY6abQ</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>123163</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Janssen Pharmaceuticals</gtr:department><gtr:description>Prediction of drug-drug interaction between Rifampicin and Boosted Darunavir using pharmacokinetic modelling approaches</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Johnson &amp; Johnson</gtr:fundingOrg><gtr:id>C2D9D64A-6D15-4249-AE27-2D344C72CB37</gtr:id><gtr:outcomeId>545109ca0e8457.33158783</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Roche Diagnostics</gtr:department><gtr:description>HEP Drug-drug Interactions Website (Roche)</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>F. Hoffmann-La Roche AG</gtr:fundingOrg><gtr:id>5912D605-704C-4806-B5E8-CF29E4F97A4C</gtr:id><gtr:outcomeId>V4MKSJso7R2</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>HEP Drug-drug Interactions Website (Gilead)</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Gilead</gtr:fundingOrg><gtr:id>2AF45B02-5937-4C70-A705-B9CD5C7877AD</gtr:id><gtr:outcomeId>JfTzSEtcuN8</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>140000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>HIV Drug-drug Interactions Website (VIIV)</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Viiv Healthcare</gtr:fundingOrg><gtr:id>806D553E-F180-4C0A-BBBF-9D9BF40B16C0</gtr:id><gtr:outcomeId>DGVg12i9gVq</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>105431</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>HIV Drug-drug Interactions Website (EJAF)</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Elton John AIDS Foundation</gtr:fundingOrg><gtr:id>F2DF642E-00E6-4B05-AF5E-1005DCDE419D</gtr:id><gtr:outcomeId>545223af3e58c0.43448349</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>198162</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>North West England MRC Fellowships in Clinical Pharmacology and Therapeutics</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G1000417</gtr:fundingRef><gtr:id>7ABA35A1-265B-418C-9CB1-9020537DED89</gtr:id><gtr:outcomeId>ETEnvUkWSzy</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>396554</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>St Stephen's AIDS Trust</gtr:department><gtr:description>SSAT Trials</gtr:description><gtr:end>2020-03-02</gtr:end><gtr:fundingOrg>Chelsea and Westminster Hospital NHS Foundation Trust</gtr:fundingOrg><gtr:id>D563A78D-BB3A-493B-9600-A9388508F967</gtr:id><gtr:outcomeId>RLUaN2eAJWg</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>130000</gtr:amountPounds><gtr:country>Australia, Commonwealth of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Kirby Institute</gtr:department><gtr:description>ENCORE Studies (Bill &amp;amp; Melinda Gates Foundation)</gtr:description><gtr:end>2014-11-02</gtr:end><gtr:fundingOrg>University of New South Wales</gtr:fundingOrg><gtr:id>B4A255D1-2AEF-47C7-BACF-ACDFC7FA5268</gtr:id><gtr:outcomeId>Y5tWFZH4VqD</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>85600</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>HIV Drug-drug Interactions Website (Merck)</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Merck</gtr:fundingOrg><gtr:id>0A94E371-117E-4BB2-BDBA-7B51FA0D89B7</gtr:id><gtr:outcomeId>DDfpUfwvAkg</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>47000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Liverpool Pancreatic Biomedical Research Unit</gtr:department><gtr:description>Computer-aided decision support for electronic prescribing, dispensing and health records of HIV positive patients</gtr:description><gtr:end>2013-02-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>0AFCFB68-C899-4CF9-9158-C1025947DEC1</gtr:id><gtr:outcomeId>ari5bAMpSZy</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>104000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>HEP Drug-drug Interactions Website (Vertex)</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Vertex Pharmaceuticals</gtr:fundingOrg><gtr:id>C6FAD487-1090-4739-8D02-9677D1B52DAE</gtr:id><gtr:outcomeId>BgCb4xLyL7z</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>57883</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>HIV Drug-drug Interactions Website (BMS)</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Bristol-Myers Squibb</gtr:fundingOrg><gtr:id>AA884827-A970-4DDE-A10F-79B52B0D00FD</gtr:id><gtr:outcomeId>YnrFEDXE6Hf</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100003</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR Biomedical Research Fellowship - Victoria Watson</gtr:description><gtr:end>2013-10-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>BRF-2011-029</gtr:fundingRef><gtr:id>8AE287E4-CAD3-48CD-9C18-0EAFA4D8C69A</gtr:id><gtr:outcomeId>AMsdmnTXQE2</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>67500</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>HEP Drug-drug Interactions Website (Merck)</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Merck</gtr:fundingOrg><gtr:id>AD254698-3A08-4184-A884-D587DF3C6366</gtr:id><gtr:outcomeId>Bd6ToGBdqHP</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>75084</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR Flexibility &amp;amp; Sustainability Funding</gtr:description><gtr:end>2011-08-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>4F283FD0-367F-4695-B835-395EC9EBCFD6</gtr:id><gtr:outcomeId>UVjqDqkpasw</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>224114</gtr:amountPounds><gtr:country>Australia, Commonwealth of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>A randomised, double-blind, placebo-controlled, clinical trial to compare the safety and efficacy of reduced dose efavirenz (EFV) with stardard dose EFV</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>University of New South Wales</gtr:fundingOrg><gtr:id>C20B1AEA-B9D2-4958-A533-AEA8E36D0F7D</gtr:id><gtr:outcomeId>BMChHp7FcVE</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>143878</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Raltegravir pharmacokinetics</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Merck</gtr:fundingOrg><gtr:id>412DA1FA-D519-4E49-84FF-250FD53A2B56</gtr:id><gtr:outcomeId>rFNTQBWqEHe</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>25000</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>HEP Drug-drug Interactions Website (BI)</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Boehringer Ingelheim</gtr:fundingOrg><gtr:id>04BC7E91-7371-45E0-B338-C2E37F37048C</gtr:id><gtr:outcomeId>btdGtWa26j1</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>53772</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>HIV Drug-drug Interactions Website (BHIVA)</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>British HIV Association (BHIVA)</gtr:fundingOrg><gtr:id>68AA3154-703C-44E2-A5EB-077CAB67B4EF</gtr:id><gtr:outcomeId>Ryz6MP1c6Wx</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>38772</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>HIV Drug-drug Interactions Website (EACS)</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>European Aids Clinical Society</gtr:fundingOrg><gtr:id>F88CB673-00D1-4B75-9CCE-589EE9B064D2</gtr:id><gtr:outcomeId>EprYedDtu4V</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>75084</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Liverpool Pancreatic Biomedical Research Unit</gtr:department><gtr:description>Liverpool Bioanalytical Facility</gtr:description><gtr:end>2011-06-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>14B5E51B-7D71-45AB-B9D7-CECF75210EA3</gtr:id><gtr:outcomeId>FeRRhjjUMMK</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>115118</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Janssen Pharmaceutica</gtr:department><gtr:description>HIV Drug-drug Interactions Website (Janssen)</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Johnson &amp; Johnson</gtr:fundingOrg><gtr:id>A9B18111-6A9C-4F8D-8CB2-0BA8D6D07812</gtr:id><gtr:outcomeId>LqFTmYSYmuW</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>149954</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Janssen Pharmaceutica</gtr:department><gtr:description>HEP Drug-drug Interactions Website (Janssen)</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Johnson &amp; Johnson</gtr:fundingOrg><gtr:id>FE495E9B-28BC-4EDC-8712-BA0AF3A849DF</gtr:id><gtr:outcomeId>iTexQfveQLL</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>25000</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>HIV Drug-drug Interactions Website (BI)</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>Boehringer Ingelheim</gtr:fundingOrg><gtr:id>4DF70DF4-2DCD-432A-B7CC-3102F7E50338</gtr:id><gtr:outcomeId>gDbYPHufabn</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>155000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>HIV Drug-drug Interactions Website (Gilead)</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Gilead</gtr:fundingOrg><gtr:id>6264DD0A-6FCB-4C39-A750-FE58B8CB2689</gtr:id><gtr:outcomeId>545211a503f565.81314921</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>HIV Drug-drug Interactions Website</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>International Congress on Drug Therapy in HIV Infection</gtr:fundingOrg><gtr:id>7A55B50A-EDF6-4DAA-B49D-6518B5C32CE0</gtr:id><gtr:outcomeId>thVQ8CP6ZTG</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1439979</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Model-based preclinical development of anti-tuberculosis drug combinations (preDICT-TB)</gtr:description><gtr:end>2017-07-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>115337</gtr:fundingRef><gtr:id>64DE4B44-4519-4376-BDEE-4C9FA3A24132</gtr:id><gtr:outcomeId>JBu1zUvbtCL</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>113048</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>A single arm, 3 phase study to determine the effect of intermittent dosing of rifampicin on the pharmacokinetics of raltegravir in healthy volunteers</gtr:description><gtr:end>2013-07-02</gtr:end><gtr:fundingOrg>Merck</gtr:fundingOrg><gtr:fundingRef>38283</gtr:fundingRef><gtr:id>233D3AAA-F88E-4AF9-A957-908751E493E2</gtr:id><gtr:outcomeId>WL9msjoXuit</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2011-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>130000</gtr:amountPounds><gtr:country>Australia, Commonwealth of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>A randomised, double-blind, placebo-controlled, clinical trial to compare the safety and efficacy of reduced dose efavirenz (EFV) with standard dose EFV</gtr:description><gtr:end>2014-05-02</gtr:end><gtr:fundingOrg>University of New South Wales</gtr:fundingOrg><gtr:id>68D0AD02-61DD-462C-930A-BD79991EA6BF</gtr:id><gtr:outcomeId>NxZCmfwgb5n</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Abbott UK</gtr:department><gtr:description>HIV Drug-drug Interactions Website (Abbott)</gtr:description><gtr:end>2010-12-02</gtr:end><gtr:fundingOrg>Abbott</gtr:fundingOrg><gtr:id>527E51E8-AE84-4519-BC60-212161FAF299</gtr:id><gtr:outcomeId>Ukf5m5xYarR</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>We developed traffic lights based system of classification for HIV and hepatitis drugs, and a GRADE-based system of evidence evaluation to achieve consistency and transparency. Supporting software- including web-based decision support software, and iPhone/ tablet/Android apps. MOU in 2013 acknowledges full ownership by Liverpool of the software and content.</gtr:description><gtr:grantRef>G0901364</gtr:grantRef><gtr:id>DF5AACA8-C9CE-4B59-937F-691FFF6129CA</gtr:id><gtr:impact>Websites: over 80,000 unique visitors/year
Smartphone apps - over 40,000 downloads between 2011-2013
Incorporation of Liverpool Decision support into national/international treatment guidelines from over 17 countries.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>fVcGVMM6d3Z</gtr:outcomeId><gtr:protection>Protection not required</gtr:protection><gtr:title>Liverpool HIV and Hepatitis Drug Interaction Websites</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Smartphone search tools for managing drug interactions. Available for iPhone, iPad and Android</gtr:description><gtr:grantRef>G0901364</gtr:grantRef><gtr:id>0F964E8D-9802-41A7-A383-A028A1A88E15</gtr:id><gtr:impact>over 50,000 downloads to date. Associated web stats- over 100,000 unique visitors/ year, incorporated into numerous national and international treatment guidelines.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>545d1094c2a182.72346414</gtr:outcomeId><gtr:protection>Copyrighted (e.g. software)</gtr:protection><gtr:title>Liverpool HIV and hepatitis drug interaction Apps</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>British Thoracic Society Guidelines on TB drug dosing in renal disease</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>037128DC-3533-4677-BB8F-F14B13830796</gtr:id><gtr:outcomeId>bhTkk9XXNe4</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>British HIV Association Standards for HIV care</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8027F827-20A5-4855-8EA6-FD6C70D666F7</gtr:id><gtr:impact>Universally implemented across UK
Forms commissioning and service auditing standards.</gtr:impact><gtr:outcomeId>ogfsK1rthiZ</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>British Guidelines for Managment of opportunistic infections in HIV</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>074994A5-186B-4114-805B-37CFD1A20FD3</gtr:id><gtr:outcomeId>FUr25i1AtkP</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>British HIV Association TB guidelines</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B925A51B-4470-4226-BF60-10EB0631BD0D</gtr:id><gtr:impact>Input into British HIV Association TB guidelines</gtr:impact><gtr:outcomeId>56dedd8b390193.40388458</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>British HIV Association HIV Treatment Gidelines</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>8879ED36-5405-487D-A745-024CF45AB051</gtr:id><gtr:impact>BHIVA standards are universally implemented in the UK, Republic of Ireland and elsewhere, and form national Standards for care.</gtr:impact><gtr:outcomeId>nKvwF77EMNd</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>WHO revised Adult Antiretroviral Guidelines</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>B7CB79F6-7AAB-4DF2-BD59-974DBCCEEF0B</gtr:id><gtr:outcomeId>cupf1HaeydE</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>www.hiv-druginteractions.org is now established as a decision support tool in around 30 guidelines from over 16 countries worldwide, as well as in WHO and European treatment guidelines</gtr:description><gtr:id>FBFF2753-64CB-4356-B849-A5CACF52954C</gtr:id><gtr:impact>see above</gtr:impact><gtr:outcomeId>fMCera3YGxV</gtr:outcomeId><gtr:stage>Wide-scale adoption</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>HIV Drug interaction website</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:url>http://www.hiv-druginteractions.org</gtr:url></gtr:productOutput><gtr:productOutput><gtr:description>Our work in Pk and pharmacogenetics of TB coupled with work on PK-PD relationship was instrumental in funding success. Liverpool is the lead institution on this grant.</gtr:description><gtr:id>0FAE82B0-A6E5-4F05-BF12-8D5BEB58A3F7</gtr:id><gtr:impact>accelerate drug development process, from preclincial through early clinical to phase III studies</gtr:impact><gtr:outcomeId>rJbxhzH4awU</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>PREDICT TB IMI Consortium (Eur 13M)</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>smartphone apps- iPhone/ Android/ iPad</gtr:description><gtr:id>210CB7AC-967A-4D4C-A591-AF42B908E1A5</gtr:id><gtr:impact>&amp;gt;22,000 downloads since introduction 18 months ago.</gtr:impact><gtr:outcomeId>feWVkWyQvdj</gtr:outcomeId><gtr:stage>Wide-scale adoption</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>HIV Drug interactions websites</gtr:title><gtr:type>Support Tool - For Medical Intervention</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>MRC funding helped to develop our bioanalytical facility, and we gained GCLP accreditation in 2011, and have maintained it annually thereafter</gtr:description><gtr:id>D757C5A2-DA15-44CA-A029-55A40C3CE45C</gtr:id><gtr:impact>4 primary publications in 2013, 11 primary publications in 2012, 8 primary publications in 2011</gtr:impact><gtr:outcomeId>gXNn91ytuWW</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>GCLP Accreditation</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The Bioanalytical Facility gained GCLP accreditation in 2011- MRC funding was an important contributor to this success. Our project funded bioanalyst was initially the facility GCLP archivist, and in 2012 was promoted to Quality Manager</gtr:description><gtr:id>CB82F694-2424-4D04-A644-EA2819B0835C</gtr:id><gtr:impact>GCLP accreditation has enabled us to undertake pivotal pharmacokinetic studies for submission to regulatory authorities. Since this was achieved, we have successfully gained master Service Agreements with Chelsea &amp;amp; Westminister Hospital, Service level agreements with Imperial, and Studies funded by Gates. Another service level agreement is currently in negotiation with the MRC HIV Clincial trials Unit. Bioanalytical research to a value of ~&amp;pound;300k/year for the past 2 years have resulted.</gtr:impact><gtr:outcomeId>rktDNqSNHYn</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Bioanalytical Capability</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>LC-MS assay for efavirenz and its 7- and 8-hydroxy metabolites, down to 5ng/mL sensitivity. Allows genotype-phenotype coorrelations, characterisation of poor metaboliser status, and investigation in plasma and CSF.</gtr:description><gtr:id>E278A636-B90A-4A40-B61E-90AA4FFDDBD8</gtr:id><gtr:impact>Studies are in progress</gtr:impact><gtr:outcomeId>KiySzqesuxp</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>efavirenz metabolite assay</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>GCP accreditation for highly secialised assays- measuring drug in tissues and cells</gtr:description><gtr:id>188AF6E6-5831-47FE-81C7-D0DE6ABFEC43</gtr:id><gtr:impact>Traction for research grants, high impact publications</gtr:impact><gtr:outcomeId>56dede21d6b811.99885547</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Renewal of GCP accrediation for labs</gtr:title><gtr:type>Biological samples</gtr:type><gtr:url>https://www.liverpool.ac.uk/translational-medicine/research/bioanalytical-facility/about/</gtr:url><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>844044FF-0FB9-4FD6-AAF9-5980704E02C2</gtr:id><gtr:title>A validated method for quantification of efavirenz in dried blood spots using high-performance liquid chromatography-mass spectrometry.</gtr:title><gtr:parentPublicationTitle>Therapeutic drug monitoring</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/26f4145d8c6f9acd7781b2401d4ae386"><gtr:id>26f4145d8c6f9acd7781b2401d4ae386</gtr:id><gtr:otherNames>Amara AB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0163-4356</gtr:issn><gtr:outcomeId>544e3007e1cab8.75082517</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32AD3338-44D8-45AF-9A2C-489A9E5D935C</gtr:id><gtr:title>Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a7d8df257e748e69522231f52f1a1bc7"><gtr:id>a7d8df257e748e69522231f52f1a1bc7</gtr:id><gtr:otherNames>Sloan DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>56cc40ec1ced96.74247696</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A0CDA06-596A-49AF-B7B9-E89D052E60B4</gtr:id><gtr:title>CYP3A4*22 (c.522-191 C&amp;gt;T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults.</gtr:title><gtr:parentPublicationTitle>Pharmacogenetics and genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9be9dbf0af92c5be7ee757afe2c5b9f5"><gtr:id>9be9dbf0af92c5be7ee757afe2c5b9f5</gtr:id><gtr:otherNames>Olagunju A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1744-6872</gtr:issn><gtr:outcomeId>544e3008b4e0a8.23048533</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84847501-F50D-42F5-A6E0-00CB5260F99E</gtr:id><gtr:title>Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3fbb2e230eb62f2242af7fb073665f45"><gtr:id>3fbb2e230eb62f2242af7fb073665f45</gtr:id><gtr:otherNames>Byakika-Kibwika P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>pm_15569_29_22316571</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D34351FB-082E-425A-A36E-AAA1C4168E9B</gtr:id><gtr:title>British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1fb3a00e279118a452043627fb54607"><gtr:id>b1fb3a00e279118a452043627fb54607</gtr:id><gtr:otherNames>Williams I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>pm_15569_29_22830364</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23D1989E-ECED-4450-A85D-D3C7D4B1797B</gtr:id><gtr:title>Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d3ee2ddacaedd29eb33b6564e7b6a0d"><gtr:id>6d3ee2ddacaedd29eb33b6564e7b6a0d</gtr:id><gtr:otherNames>Else LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>pm_15569_29_22183172</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DBE253D-4414-48FF-9959-BC96D00AC99A</gtr:id><gtr:title>Drug-drug interactions between antiretrovirals and drugs used in the management of neglected tropical diseases: important considerations in the WHO 2020 Roadmap and London Declaration on Neglected Tropical Diseases.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/432c6c60c5924bcdaa17a340272c8f8b"><gtr:id>432c6c60c5924bcdaa17a340272c8f8b</gtr:id><gtr:otherNames>Seden K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_15569_29_23719345</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>132CC703-88CC-4E7C-8247-2E57B117FF9F</gtr:id><gtr:title>The clinical utility of HIV outpatient pharmacist prescreening to reduce medication error and assess adherence.</gtr:title><gtr:parentPublicationTitle>International journal of STD &amp; AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/432c6c60c5924bcdaa17a340272c8f8b"><gtr:id>432c6c60c5924bcdaa17a340272c8f8b</gtr:id><gtr:otherNames>Seden K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0956-4624</gtr:issn><gtr:outcomeId>pm_15569_29_23562967</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01C45A4E-E780-4FAE-B0DD-14C90D5A5E10</gtr:id><gtr:title>Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3fbb2e230eb62f2242af7fb073665f45"><gtr:id>3fbb2e230eb62f2242af7fb073665f45</gtr:id><gtr:otherNames>Byakika-Kibwika P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>pm_15569_29_22687893</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83A4592A-FCDE-49CA-8DF3-F1012E55CFAF</gtr:id><gtr:title>Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trial.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e11668afe47c6624eb66cf3d5932f65a"><gtr:id>e11668afe47c6624eb66cf3d5932f65a</gtr:id><gtr:otherNames>Winston A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>56cc40ed361fd8.69089406</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>970BCC05-B50A-48AF-884E-64678F55DF57</gtr:id><gtr:title>Opinion: the pharmacometrics of infectious disease.</gtr:title><gtr:parentPublicationTitle>CPT: pharmacometrics &amp; systems pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd0bd9d624f992d94fa7c0f219fb2903"><gtr:id>fd0bd9d624f992d94fa7c0f219fb2903</gtr:id><gtr:otherNames>Davies GR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2163-8306</gtr:issn><gtr:outcomeId>pm_15569_29_23985968</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F4B2463-A673-41F1-9E93-2E3B3DAFFB6C</gtr:id><gtr:title>Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs.</gtr:title><gtr:parentPublicationTitle>Pharmacogenetics and genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bd89e08bfb4c7846101701582e9c34f6"><gtr:id>bd89e08bfb4c7846101701582e9c34f6</gtr:id><gtr:otherNames>Urban TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1744-6872</gtr:issn><gtr:outcomeId>pm_15569_29_22968431</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0E05EC0-AA30-449A-9344-5B95F1BB6428</gtr:id><gtr:title>Ageing with HIV: medication use and risk for potential drug-drug interactions.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e965dfe53e1320f8ec73fc259160d2f"><gtr:id>8e965dfe53e1320f8ec73fc259160d2f</gtr:id><gtr:otherNames>Marzolini C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>pm_15569_29_21680580</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF748BCB-FC0F-4F6C-B113-F7381E98A3C4</gtr:id><gtr:title>Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b25b38c6de5dd5ca3dd8689559837fe4"><gtr:id>b25b38c6de5dd5ca3dd8689559837fe4</gtr:id><gtr:otherNames>Lamorde M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>pm_15569_29_21047828</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4B0D046-01D8-49B3-826F-015568AF4C70</gtr:id><gtr:title>Population pharmacokinetic analysis of isoniazid, acetylisoniazid, and isonicotinic acid in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eef10a1c493377fe7c64909627cbea71"><gtr:id>eef10a1c493377fe7c64909627cbea71</gtr:id><gtr:otherNames>Seng KY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>56cc40ea139d45.58020820</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0B55BEA-C30B-4378-B63A-ADCFAC2C4F3E</gtr:id><gtr:title>Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults.</gtr:title><gtr:parentPublicationTitle>AIDS research and treatment</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b25b38c6de5dd5ca3dd8689559837fe4"><gtr:id>b25b38c6de5dd5ca3dd8689559837fe4</gtr:id><gtr:otherNames>Lamorde M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2090-1240</gtr:issn><gtr:outcomeId>pm_15569_29_22454762</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E19623D-8B95-4933-B3F3-2C2C50D35E20</gtr:id><gtr:title>HIV associated neurocognitive disorders (HAND) in Malawian adults and effect on adherence to combination anti-retroviral therapy: a cross sectional study.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9dd96bb733c0726221ef84de4144119"><gtr:id>f9dd96bb733c0726221ef84de4144119</gtr:id><gtr:otherNames>Kelly CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>544e3008e1c173.25152367</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F9A99FF-F99F-48A2-8013-A83061FA4D3E</gtr:id><gtr:title>Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/817eda19ac6c2a80aef0b19b6f166780"><gtr:id>817eda19ac6c2a80aef0b19b6f166780</gtr:id><gtr:otherNames>Boffito M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>pm_15569_29_21709075</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F62F46E0-5962-43AE-8FC5-C2D976633261</gtr:id><gtr:title>Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d3ee2ddacaedd29eb33b6564e7b6a0d"><gtr:id>6d3ee2ddacaedd29eb33b6564e7b6a0d</gtr:id><gtr:otherNames>Else LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>pm_15569_29_22106215</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9C1FE80-7444-4D18-B2C9-AC2C5654A9C4</gtr:id><gtr:title>13 A-Z of drugs used in the treatment of opportunist infections in HIV (Appendix 1)</gtr:title><gtr:parentPublicationTitle>HIV Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00ca067bbf9e3b99aacdfa65e0865a00"><gtr:id>00ca067bbf9e3b99aacdfa65e0865a00</gtr:id><gtr:otherNames>Weston R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>Rdys3iWKSBD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DA80491-D990-48B3-B1C5-BA4342D67FD1</gtr:id><gtr:title>Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71a1a0f61637467c2409a047740cd2fa"><gtr:id>71a1a0f61637467c2409a047740cd2fa</gtr:id><gtr:otherNames>Waitt C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>5aa7eb45281918.53286870</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58622178-323A-4CD0-99EC-9CDBC4CD24F1</gtr:id><gtr:title>Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d3ee2ddacaedd29eb33b6564e7b6a0d"><gtr:id>6d3ee2ddacaedd29eb33b6564e7b6a0d</gtr:id><gtr:otherNames>Else LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>pm_15569_29_22155899</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70CF4FB2-9CB3-42D9-869B-CEB2A8D817DC</gtr:id><gtr:title>Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9be9dbf0af92c5be7ee757afe2c5b9f5"><gtr:id>9be9dbf0af92c5be7ee757afe2c5b9f5</gtr:id><gtr:otherNames>Olagunju A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>56cc40eb80ce87.51228916</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CBD75735-7615-43CD-B457-AFFC1F71CFD8</gtr:id><gtr:title>Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e4d57e7ccac0cf1e7cbdb915c51fa748"><gtr:id>e4d57e7ccac0cf1e7cbdb915c51fa748</gtr:id><gtr:otherNames>Waitt CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>56cc40ebbe6b07.89211939</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>693787D2-86E1-4E7B-A3F2-1CC4E17BAAAD</gtr:id><gtr:title>Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600&amp;nbsp;mg in Treatment-Na&amp;iuml;ve HIV-Infected Patients at 96&amp;nbsp;Weeks: Results of the ENCORE1 Study.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacokinetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c97efd9e846f66e37e723bed51b279e"><gtr:id>0c97efd9e846f66e37e723bed51b279e</gtr:id><gtr:otherNames>Dickinson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0312-5963</gtr:issn><gtr:outcomeId>56cc40e83aa9a0.17234343</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51E75D69-4295-495F-A180-14A7FC0094EF</gtr:id><gtr:title>HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms.</gtr:title><gtr:parentPublicationTitle>Pharmacogenetics and genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a115960aa50380c50c0fbcd79cbae81"><gtr:id>4a115960aa50380c50c0fbcd79cbae81</gtr:id><gtr:otherNames>Hartkoorn RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1744-6872</gtr:issn><gtr:outcomeId>pm_15569_29_20051929</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F2CDDD2-CF1D-476B-9BD5-0EA284672AB1</gtr:id><gtr:title>Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49e9f1ecf5e64a2529be53310e81c399"><gtr:id>49e9f1ecf5e64a2529be53310e81c399</gtr:id><gtr:otherNames>Schipani A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>pm_15569_29_22477766</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B226C77C-400A-4DE5-AC5F-66C418B6390F</gtr:id><gtr:title>Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a7d8df257e748e69522231f52f1a1bc7"><gtr:id>a7d8df257e748e69522231f52f1a1bc7</gtr:id><gtr:otherNames>Sloan DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>5aa7eb694fc189.34342949</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DFEFF9A-BE53-4296-B8EB-AFB8E4583188</gtr:id><gtr:title>Effect of intermittent rifampicin on the pharmacokinetics and safety of raltegravir.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/015859493472dac110a6ccdbc8102f07"><gtr:id>015859493472dac110a6ccdbc8102f07</gtr:id><gtr:otherNames>Reynolds HE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>544e30073753e2.03080419</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8EC7EEB-C61E-49FD-BFA3-14C3832AB7AF</gtr:id><gtr:title>Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d3ee2ddacaedd29eb33b6564e7b6a0d"><gtr:id>6d3ee2ddacaedd29eb33b6564e7b6a0d</gtr:id><gtr:otherNames>Else LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>pm_15569_29_22155898</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8385C1B6-3DEA-499D-B20D-E7B84795B72E</gtr:id><gtr:title>Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9be9dbf0af92c5be7ee757afe2c5b9f5"><gtr:id>9be9dbf0af92c5be7ee757afe2c5b9f5</gtr:id><gtr:otherNames>Olagunju A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>56cc40ecae4ad4.62773730</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0608B39D-40A0-40BD-812C-CD483C4E82D1</gtr:id><gtr:title>British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/782866de2b1b9f67d69dd942fc74dba4"><gtr:id>782866de2b1b9f67d69dd942fc74dba4</gtr:id><gtr:otherNames>Nelson M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>pm_15569_29_21851517</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DE3789E-3AA6-4C24-BBAC-E00A57AF5F4D</gtr:id><gtr:title>Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c97efd9e846f66e37e723bed51b279e"><gtr:id>0c97efd9e846f66e37e723bed51b279e</gtr:id><gtr:otherNames>Dickinson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>pm_540e16de16d9d7c99</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>223AD89F-EA2C-4C18-80F4-30CC686C23F4</gtr:id><gtr:title>Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c97efd9e846f66e37e723bed51b279e"><gtr:id>0c97efd9e846f66e37e723bed51b279e</gtr:id><gtr:otherNames>Dickinson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>56cc40e877cd78.74154890</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C585EC96-B180-40DF-8FD6-5F42706C4AD5</gtr:id><gtr:title>Optimizing outpatient serial sputum colony counting for studies of tuberculosis treatment in resource-poor settings.</gtr:title><gtr:parentPublicationTitle>Journal of clinical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a7d8df257e748e69522231f52f1a1bc7"><gtr:id>a7d8df257e748e69522231f52f1a1bc7</gtr:id><gtr:otherNames>Sloan DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0095-1137</gtr:issn><gtr:outcomeId>pm_15569_29_22573593</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>493412DA-EC14-4D0E-9FFB-E1A081C7DA01</gtr:id><gtr:title>Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/22d9f42603e86f730a52fe9983ff6373"><gtr:id>22d9f42603e86f730a52fe9983ff6373</gtr:id><gtr:otherNames>Evans-Jones JG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>pm_15569_29_20380564</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CBD5E69-F303-4898-9F67-2118166E699A</gtr:id><gtr:title>Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49e9f1ecf5e64a2529be53310e81c399"><gtr:id>49e9f1ecf5e64a2529be53310e81c399</gtr:id><gtr:otherNames>Schipani A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>pm_15569_29_21441248</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4849E5B-5EAB-4568-A0E0-04756CF08939</gtr:id><gtr:title>Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.</gtr:title><gtr:parentPublicationTitle>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e2bc25928bf498eb15241bd72cb68c89"><gtr:id>e2bc25928bf498eb15241bd72cb68c89</gtr:id><gtr:otherNames>Else L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1570-0232</gtr:issn><gtr:outcomeId>pm_15569_29_20427248</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2F91E86-C09A-4C68-A956-33B423FB5198</gtr:id><gtr:title>Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b25b38c6de5dd5ca3dd8689559837fe4"><gtr:id>b25b38c6de5dd5ca3dd8689559837fe4</gtr:id><gtr:otherNames>Lamorde M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_15569_29_23698061</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3941404A-B0E2-4C3A-A315-04960D87C14A</gtr:id><gtr:title>Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f966db23a09b19b29dbbcba992446889"><gtr:id>f966db23a09b19b29dbbcba992446889</gtr:id><gtr:otherNames>Sarfo FS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>544e3033246ad5.83455764</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77D24EA9-EDCA-4B8D-A9F2-CF9D813BA67D</gtr:id><gtr:title>A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49e9f1ecf5e64a2529be53310e81c399"><gtr:id>49e9f1ecf5e64a2529be53310e81c399</gtr:id><gtr:otherNames>Schipani A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>56cc40e8d3b7b6.59170891</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25BE578F-980F-4998-9DF0-70F989C414EA</gtr:id><gtr:title>Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohort.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ec6b554f4908332610be3529ea65fae"><gtr:id>8ec6b554f4908332610be3529ea65fae</gtr:id><gtr:otherNames>Kigen G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_15569_29_21373194</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58D5B4CB-DFE4-4A08-BDBA-FDE04E0EFD72</gtr:id><gtr:title>Artemether-Lumefantrine Combination Therapy for Treatment of Uncomplicated Malaria: The Potential for Complex Interactions with Antiretroviral Drugs in HIV-Infected Individuals.</gtr:title><gtr:parentPublicationTitle>Malaria research and treatment</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3fbb2e230eb62f2242af7fb073665f45"><gtr:id>3fbb2e230eb62f2242af7fb073665f45</gtr:id><gtr:otherNames>Byakika-Kibwika P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>pm_15569_29_22312573</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6A40956-7905-4B53-9F8D-9980255F277E</gtr:id><gtr:title>Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacokinetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49e9f1ecf5e64a2529be53310e81c399"><gtr:id>49e9f1ecf5e64a2529be53310e81c399</gtr:id><gtr:otherNames>Schipani A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0312-5963</gtr:issn><gtr:outcomeId>544e3007a7afa6.30328596</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>164C84BD-2120-463C-9BD7-2AC664846F52</gtr:id><gtr:title>Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan Adults.</gtr:title><gtr:parentPublicationTitle>Chemotherapy research and practice</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3fbb2e230eb62f2242af7fb073665f45"><gtr:id>3fbb2e230eb62f2242af7fb073665f45</gtr:id><gtr:otherNames>Byakika-Kibwika P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2090-2107</gtr:issn><gtr:outcomeId>pm_15569_29_22312553</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65749EB5-0E4A-44FC-8A57-5290597EE774</gtr:id><gtr:title>Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e11668afe47c6624eb66cf3d5932f65a"><gtr:id>e11668afe47c6624eb66cf3d5932f65a</gtr:id><gtr:otherNames>Winston A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>pm_15569_29_23435690</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C5A5D41-9358-46C3-9CAC-EEAC5A63D934</gtr:id><gtr:title>Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9be9dbf0af92c5be7ee757afe2c5b9f5"><gtr:id>9be9dbf0af92c5be7ee757afe2c5b9f5</gtr:id><gtr:otherNames>Olagunju A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>544e300700a5b6.98786234</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F57CE4D7-092A-45ED-9A02-6675C1764285</gtr:id><gtr:title>Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 Study.</gtr:title><gtr:parentPublicationTitle>Therapeutic drug monitoring</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/26f4145d8c6f9acd7781b2401d4ae386"><gtr:id>26f4145d8c6f9acd7781b2401d4ae386</gtr:id><gtr:otherNames>Amara AB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0163-4356</gtr:issn><gtr:outcomeId>5aa7ec4f881115.06563586</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20D1C36B-3389-4695-A99B-2B1EFBC947C1</gtr:id><gtr:title>Standards of Care for People living with HIV 2013</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59ad4d7502e2a1cfc306fae7ba284f26"><gtr:id>59ad4d7502e2a1cfc306fae7ba284f26</gtr:id><gtr:otherNames>British HIV Association</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:isbn>978-0-9551669-4-5</gtr:isbn><gtr:outcomeId>hw2Xt7JriDi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D84A3993-4640-4CF0-8AB8-40915EDE889D</gtr:id><gtr:title>Population pharmacokinetics of rifampicin and 25-deacetyl-rifampicin in healthy Asian adults.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eef10a1c493377fe7c64909627cbea71"><gtr:id>eef10a1c493377fe7c64909627cbea71</gtr:id><gtr:otherNames>Seng KY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>56cc40e93ba5e9.38815575</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48DA6EDB-7B6C-49C8-8E8D-668B2D6D1185</gtr:id><gtr:title>Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease.</gtr:title><gtr:parentPublicationTitle>Thorax</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9945575e83ea38ce29698e9bfa8496f4"><gtr:id>9945575e83ea38ce29698e9bfa8496f4</gtr:id><gtr:otherNames>British Thoracic Society Standards of Care Committee and Joint Tuberculosis Committee</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0040-6376</gtr:issn><gtr:outcomeId>pm_15569_29_20522863</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CCE5D405-9BF7-42E4-B8DE-5990B50E22E0</gtr:id><gtr:title>CYP2B6 c.983T&amp;gt;C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9f327f341d1d6e5d479cd9c2652283b"><gtr:id>c9f327f341d1d6e5d479cd9c2652283b</gtr:id><gtr:otherNames>Carr DF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>544e3008521386.71576639</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F89CE3D-E849-4058-9892-5F13FA83630E</gtr:id><gtr:title>Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis.</gtr:title><gtr:parentPublicationTitle>EBioMedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85763c2ccefcc71dc718b20f1f572a43"><gtr:id>85763c2ccefcc71dc718b20f1f572a43</gtr:id><gtr:otherNames>Cummins NW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2352-3964</gtr:issn><gtr:outcomeId>56cc40e99e4c06.82245093</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E2DA0D4-9E30-4763-A161-5455314D1F07</gtr:id><gtr:title>Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e965dfe53e1320f8ec73fc259160d2f"><gtr:id>8e965dfe53e1320f8ec73fc259160d2f</gtr:id><gtr:otherNames>Marzolini C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>pm_15569_29_20516560</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00953EF5-3A61-41C5-939A-F945B8325D62</gtr:id><gtr:title>Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b25b38c6de5dd5ca3dd8689559837fe4"><gtr:id>b25b38c6de5dd5ca3dd8689559837fe4</gtr:id><gtr:otherNames>Lamorde M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>56cc40ed0243b1.95908550</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0901364</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>